PROLOR Biotech's Longer-acting Human Growth Hormone Receives Orphan Drug Designation in Europe

-PROLOR to Receive 10 Years of Marketing Exclusivity in Europe for Longer-Acting Human Growth Hormone Products Upon Launch of hGH-CTP-
-Broad Designation for Treatment of Growth Hormone Deficiency Includes Both Adults and Children-
-First-Ever Growth Hormone Product to Receive Orphan Status in Europe-

PROLOR Biotech, Inc. (NYSE MKT: PBTH) today announced that the European Commission and the European Medicines Agency (EMA) have granted orphan drug designation to hGH-CTP, PROLOR's longer-acting version of human growth hormone in development for the treatment of growth hormone deficiency.  PROLOR will receive 10 years of marketing exclusivity in Europe for hGH-CTP, beginning at product launch.  This is the first time a growth hormone product has received orphan drug designation in Europe.

Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration

Pharmacyclics, Inc. (the "Company") (PCYC) announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to the investigational oral agent ibrutinib monotherapy for the treatment of patients with relapsed or refractory mantle cell lymphoma (MCL) and to ibrutinib monotherapy for the treatment of patients with Waldenstrom's macroglobulinemia (WM), both of which are B-cell malignancies.

StemCells, Inc. Announces First Patient Cohort Completes Spinal Cord Injury Trial - Gains in Sensory Function Persist 12 Months After Stem Cell Transplant

Improvement From Complete to Incomplete Injury Observed in One Patient

StemCells, Inc. (STEM) today announced that the twelve-month data from the first patient cohort in the Company's Phase I/II clinical trial of its proprietary HuCNS-SC(R) product candidate (purified human neural stem cells) for chronic spinal cord injury continued to demonstrate a favorable safety profile, and showed that the considerable gains in sensory function observed in two of the three patients at the six-month assessment have persisted. The third patient remains stable. A summary of the data was presented today by Martin McGlynn, President and CEO, at the 15^th Annual BIO CEO & Investor Conference. By completing the twelve-month assessment, the first patient cohort has now completed the trial, and has entered into a separate follow-up study for long-term observation.

Oncolytics Biotech® Inc. Announces Additional Positive REOLSYIN® Clinical Trial Data from Phase 2 Study in Squamous Cell Carcinoma of the Lung

Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC.TO - News) (NASDAQ:ONCY - News) today announced results examining percent overall tumour shrinkage data from its U.S. Phase 2 clinical trial in patients with squamous cell carcinoma of the lung (SCCLC) using intravenous administration of REOLYSIN^® in combination with carboplatin and paclitaxel (REO 021).

The analysis examined percent best overall tumour changes between pre-treatment and up to six treatment cycles. Of 20 evaluable patients, 19 (95%) exhibited overall tumour shrinkage, (mean (20 patients): 33.7% shrinkage). A waterfall graph showing individual patient data will be available on the Company's website at http://www.oncolyticsbiotech.com/presentations.